Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.

Goh C, Churilov L, Mitchell P, Dowling R, Yan B.

AJNR Am J Neuroradiol. 2013 Apr;34(4):721-6. doi: 10.3174/ajnr.A3418. Epub 2012 Dec 28.

2.

Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms.

Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease JL, Tubman DE.

J Neurointerv Surg. 2014 Dec;6(10):767-73. doi: 10.1136/neurintsurg-2013-010976. Epub 2013 Dec 18.

PMID:
24353331
3.
4.

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.

Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, von Beckerath N, Kastrati A.

J Thromb Haemost. 2010 Feb;8(2):250-6. doi: 10.1111/j.1538-7836.2009.03709.x. Epub 2009 Nov 28.

5.

Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting.

Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H, Berenstein A, Chong J.

AJNR Am J Neuroradiol. 2013 Apr;34(4):716-20. doi: 10.3174/ajnr.A3405. Epub 2012 Nov 29.

6.

Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience.

Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME.

AJNR Am J Neuroradiol. 2008 Aug;29(7):1389-94. doi: 10.3174/ajnr.A1070. Epub 2008 May 15.

7.

Platelet-function testing in patients undergoing neurovascular procedures: caught between a rock and a hard place.

Comin J, Kallmes DF.

AJNR Am J Neuroradiol. 2013 Apr;34(4):730-4. doi: 10.3174/ajnr.A3440. Epub 2012 Dec 20.

8.

The roles and issues of P2Y12 percent inhibition assessed by VerifyNow assay for patients undergoing Neurointervention: a prospective study.

Kashiwazaki D, Kuwayama N, Akioka N, Hayakawa Y, Kuroda S.

J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1830-6. doi: 10.1016/j.jstrokecerebrovasdis.2014.04.014. Epub 2014 Jun 21.

PMID:
24957307
9.

Influence of oral antiplatelet therapy on hemorrhagic complications of pacemaker implantation.

Said SM, Esperer HD, Hahn J, Bollmann A, Richter S, Rauwolf T, Prondzinsky R, Schmeisser A, Braun-Dullaeus RC.

Clin Res Cardiol. 2013 May;102(5):345-9. doi: 10.1007/s00392-013-0543-8. Epub 2013 Feb 6.

PMID:
23386254
10.

Effect of platelet inhibition on bleeding complications in trauma patients on preinjury clopidogrel.

Short S, Kram B, Taylor S, Cheng J, Ali K, Vasquez D.

J Trauma Acute Care Surg. 2013 Jun;74(6):1419-24. doi: 10.1097/TA.0b013e31828dac3e.

PMID:
23694867
11.

Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.

Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ.

Circulation. 2004 Aug 24;110(8):994-8. Epub 2004 Aug 9.

12.

Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery.

Stone DH, Goodney PP, Schanzer A, Nolan BW, Adams JE, Powell RJ, Walsh DB, Cronenwett JL; Vascular Study Group of New England.

J Vasc Surg. 2011 Sep;54(3):779-84. doi: 10.1016/j.jvs.2011.03.003. Epub 2011 May 14.

13.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
15.

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.

Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators.

Circulation. 2005 Jun 28;111(25):3366-73. Epub 2005 Jun 20.

16.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.

Clin Ther. 2010 Feb;32(2):365-79. doi: 10.1016/j.clinthera.2010.02.015.

PMID:
20206794
17.
18.

Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose.

Pandya DJ, Fitzsimmons BF, Wolfe TJ, Hussain SI, Lynch JR, Ortega-Gutierrez S, Zaidat OO.

J Neuroimaging. 2010 Jan;20(1):64-9. doi: 10.1111/j.1552-6569.2008.00322.x.

PMID:
19018951
19.

Femoral artery complications after cardiac catheterization: a study of patient profile.

Castillo-Sang M, Tsang AW, Almaroof B, Cireddu J, Sferra J, Zelenock GB, Engoren M, Kasper G.

Ann Vasc Surg. 2010 Apr;24(3):328-35. doi: 10.1016/j.avsg.2009.06.025. Epub 2009 Sep 11.

PMID:
19748217
20.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

Items per page

Supplemental Content

Write to the Help Desk